SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Neurology (movement disorders) Consultation — Muhammad Ali — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Muhammad Ali |
|---|
| Date of birth | 1942-01-17 |
|---|
| Identifiers | MRN HR-BX001-SYN-TD; SSN (made up) 000-01-7724 |
|---|
| Document date | 1996-03-10 |
|---|
| Author | Kwame Asante, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Young-onset Parkinson's disease, diagnosed twelve years ago at 42, in a 54-year-old man whose slowness of movement now limits daily tasks on a modest levodopa dose. Please review the diagnosis, advise on the levodopa dose or another agent, and plan rehabilitation for his soft speech and gait. [S]
Urgency: Routine, within four weeks, on the same day as his four-week primary care check. [S]
Questions for the consultant:
- Does he meet the MDS criteria for Parkinson's disease, given the young onset and the earlier description of a parkinsonian syndrome related to boxing, and is brain imaging needed?
- Should levodopa be increased, or another agent added, for the bradykinesia?
- What rehabilitation do you advise for his soft speech and his gait and balance?
- Should genetic testing be offered?
- How often should he be followed, and by whom?
History of Present Illness
Mr. Ali, a 54-year-old man with parkinsonism diagnosed twelve years ago at 42, is seen at the request of Dr. Moreau. Slowness of movement is his main limitation: buttoning, handwriting, and rising from low chairs take longer, most of all in the late morning and late afternoon. He has a mild right-hand tremor at rest. His voice is soft, and people have trouble hearing him in crowds. He takes carbidopa-levodopa 25/100 mg one tablet three times a day, often with meals, and notices no wearing-off before doses, no involuntary movements, no freezing, and no lightheadedness on standing. He has had no falls, hallucinations, dream enactment, or new urges to gamble, shop, or eat. He boxed professionally until three years before the diagnosis. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Muhammad Ali was born Cassius Clay in Louisville, Kentucky, on January 17, 1942. [D]
- In 1984, at age 42 and three years after he retired from boxing, Ali was diagnosed with a parkinsonian condition by the neurologist Stanley Fahn in New York; it has been publicly described as Parkinson's disease since. [D]
- The diagnosing neurologist later said publicly that slowness of movement was Ali's main limitation at the time of diagnosis, with a masked face, decreased blinking, a typical parkinsonian tremor, and a shuffling gait, and that some features were too early for classic Parkinson's disease. [D]
- In a 1996 television interview, Ali's physician Dennis Cope described his condition as Parkinson's syndrome attributed to pugilistic brain syndrome from boxing, and said testing showed his cognitive function had not declined: "His mind is fine." [D]
- Whether boxing caused Ali's Parkinson's disease is disputed. The diagnosing neurologist thought the early symptoms were probably caused by repeated blows to the head but could not be certain; his later physician Abraham Lieberman did not think boxing contributed, though he was not a hundred percent certain; and the director of the Muhammad Ali Parkinson Center said there was no medical evidence that boxing contributed. [R]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 1984-10-01 to 1996-03-10 | completed | S |
| Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals | One and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before meals | Oral route | 1996-03-10 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed |
G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed |
R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |
Physical Exam
Vital signs recorded on 1996-03-10; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Alert, humorous, and engaged; reduced facial expression and blinking |
| Mental status | Fully oriented; fluent, coherent speech, soft and monotone |
| Eye movements | Full range, including vertical gaze; slightly slowed saccades; no square-wave jerks |
| Motor | MDS-UPDRS Part III 30 in the on state, about two hours after a dose. Bradykinesia with decrement on finger and foot tapping, worse on the right; rigidity in all limbs, worse on the right; mild right-hand rest tremor; no dyskinesia, dystonia, or myoclonus |
| Coordination and reflexes | No cerebellar signs; reflexes symmetric; plantar responses flexor |
| Gait | Short steps with reduced arm swing; no freezing; recovers after three steps on the pull test; Hoehn and Yahr stage 2.5 |
| Orthostatic check | 128/80 mmHg supine and 122/78 mmHg at 3 minutes standing, without symptoms |
Assessment
- Parkinson's disease, young onset, Hoehn and Yahr stage 2.5 (G20.A1). Clinically established Parkinson's disease by the MDS criteria: bradykinesia with rest tremor and rigidity, a clear and lasting response to levodopa, and no red flags or absolute exclusions. There is no early falling, no vertical gaze palsy, no cerebellar or pyramidal sign, no early autonomic failure, and no early dementia. Whether repeated blows to the head in his boxing career contributed cannot be confirmed or excluded during life. The course and examination are those of Parkinson's disease, and the question does not change his treatment. [S]
- Bradykinesia on a modest levodopa dose. Bradykinesia limits daily tasks on levodopa 100 mg three times daily, with no motor complications. Taking doses with meals blunts absorption. Raising levodopa is the simplest and best-tolerated step. A dopamine agonist would add risks of sleepiness, impulse-control disorders, and hallucinations, and an MAO-B inhibitor would add only a small benefit. [S]
- Hypokinetic dysarthria with soft speech (R47.1). Soft, monotone speech typical of Parkinson's disease, which responds well to intensive voice treatment. [S]
- Gait, balance, and fall risk. No falls, but short steps and a three-step pull-test recovery show early postural instability. Supervised exercise and balance training lower fall risk and improve gait. [S]
- Genetic testing. Genetic testing with counseling is now offered to everyone with Parkinson's disease, and young onset makes it more informative. The result would not change his current treatment. [S]
Data reviewed: Dr. Moreau's first-visit assessment four weeks ago: MDS-UPDRS Part III 30, Hoehn and Yahr stage 2.5, Timed Up and Go 13 seconds, pull test, supine and standing blood pressure, MoCA 27, PHQ-9 3, EAT-10 2, sleep and impulse-control screens; blood count, chemistry, vitamin B12, and TSH from the same visit; and today's supine and standing blood pressure. [S]
Plan of Treatment
- Increase carbidopa-levodopa to one and a half 25/100 mg tablets (levodopa 150 mg) three times daily, taken 30 minutes before meals, and spread protein through the day. [S]
- Check supine and three-minute standing blood pressure at the next visit after the increase; report lightheadedness, involuntary movements, nausea, or sleepiness. [S]
- No dopamine agonist or MAO-B inhibitor for now; review if motor fluctuations appear. [S]
- Avoid dopamine-blocking drugs (metoclopramide, prochlorperazine, and antipsychotics other than quetiapine, clozapine, or pimavanserin); use ondansetron if an antiemetic is needed. [S]
- Four-week intensive speech therapy course (LSVT LOUD), then daily voice practice. [S]
- Physical therapy for gait and balance, building to at least 150 minutes a week of aerobic, strength, and balance exercise. [S]
- No brain imaging or laboratory workup is needed, because there are no atypical features. [S]
- Genetic testing with counseling offered today; he will decide at the yearly review. [S]
- Primary care follows him every three months on the CMID schedule, with motor examination, Hoehn and Yahr stage, fall check, orthostatic blood pressure, and psychosis and impulse-control questions at each visit, and cognition, mood, sleep, autonomic, swallowing, and speech screens yearly. [S]
- Discussed with Dr. Moreau, who sees him the same day. The plan was explained to Mr. Ali, who agreed to it. [S]
- Follow-up: Movement disorders review in one year, or sooner for motor fluctuations, dyskinesia, falls, hallucinations, or a cognitive change. [S]